Skip to content
Open access

Effectiveness of a bivalent RSV prefusion F protein-based vaccine in individuals with and without atherosclerotic cardiovascular disease: a prespecified analysis of the DAN-RSV trial

Oct 2026 · European Heart Journal · Vol 47 · 0 citations

TL;DR

A prespecified analysis of the complete two-season DAN-RSV trial cohort will examine the vaccine effectiveness (VE) of RSVpreF versus no vaccine on respiratory and CV events among participants with or without pre-existing ASCVD.

Abstract

Respiratory syncytial virus (RSV) is associated with an increased risk of cardiovascular (CV) events, particularly among individuals with pre-existing CV disease. A bivalent RSV prefusion F protein-based (RSVpreF) vaccine demonstrated effectiveness against RSV-related hospitalization outcomes in the first season of the DAN-RSV trial, without significant heterogeneity between participants with and without atherosclerotic CV disease (ASCVD). However, the study was not adequately powered to detect potential differences in CV events. This prespecified analysis of the complete two-season DAN-RSV trial cohort will examine the vaccine effectiveness (VE) of RSVpreF versus no vaccine on respiratory and CV events among participants with or without pre-existing ASCVD. DAN-RSV (NCT06684743) is a pragmatic, open-label, individually randomized trial conducted during the 2024/2025 and 2025/2026 winter seasons. In season one, individuals aged ≥60 years were enrolled in Denmark. In season two, individuals aged ≥18 years are being enrolled in Denmark and Galicia, Spain (Figure). Across both seasons, recruitment in Denmark is mainly electronic, using the Danish governmental electronic mail system, while recruitment in Galicia is mainly in-person at primary care and hospital-based appointments. Participants are individually randomized 1:1 to RSVpreF or no vaccine. Baseline and outcome data are collected through linkage to regional and national registries. Participants are followed for clinical outcomes from 14 days after vaccination/booked study visit through May 31 of each season. The primary outcome is RSV-related respiratory tract disease hospitalization. This prespecified analysis will focus on a wide range of CV outcomes, e.g., CV hospitalization, major adverse cardiovascular events, and heart failure hospitalization, in individuals with or without a history of ASCVD. Incidence rates and VE, including the potential effect modification of ASCVD, will be reported. In season one of the DAN-RSV trial, 131,276 participants were randomized, of whom 14,241 (11%) had a history of ASCVD. The results suggested a potential reduction in all-cause CV hospitalization. The VE was similar among individuals with pre-existing ASCVD versus those without except for stroke, the risk of which was significantly reduced by the RSVpreF vaccine in persons with ASCVD. In season two, 331,601 participants (44% men) have been randomized in Denmark and >50,000 (48% men) in Galicia, rendering a total study population of >510,000. The ASCVD cohort is expected to exceed 35,000. The final outcome data will be available for presentation at the ESC Congress. DAN-RSV is the first randomized RSV vaccine trial to evaluate VE against CV outcomes. Its large sample size, pragmatic design, and addition of diverse geographic locations support a robust assessment of RSVpreF VE in individuals with and without ASCVD.Trial Flow Diagram.

Read PDF

Similar papers

Open access Oct 2026

Effect of bivalent RSV prefusion F protein-based vaccine on myocarditis and pericarditis: a prespecified safety analysis of the DAN-RSV trial

Myocarditis and pericarditis are inflammatory cardiac syndromes that have been monitored as outcomes of special interest in adult vaccination programs. Previous randomized and observational studies of RSVpreF vaccination have not identified an association with these events; however, given their low incidence, pri...

M. Yafasov, M. Pareek, M. Lassen et al. · 0 citations
Open access Oct 2026

Effectiveness of RSV vaccine against cardio-respiratory hospitalizations in heart failure: a prespecified analysis of the DAN-RSV trial

Individuals living with heart failure (HF) are predisposed to severe cardio-respiratory disease (CRD) complications following respiratory syncytial virus (RSV) infection. A bivalent RSV prefusion F protein-based (RSVpreF) vaccine reduced the risk of hospitalization for RSV-related respiratory tract disease (RTD),...

K. Skaarup, M. Lassen, M. Yafasov et al. · 0 citations
Open access Sep 2026

Clinical and economic benefits of bivalent Respiratory syncytial virus prefusion F (RSVpreF) vaccine for prevention of RSV in adults: a cost-effectiveness analysis for Singapore.

RSVpreF vaccination would substantially reduce the clinical and economic burden of RSV among adults in Singapore and be cost-effective under a threshold of 1 ×gross domestic product per capita per QALY gained.

K. Thakkar, A. Shajarizadeh, Nishu Gaind et al. · 0 citations
#protein folding Open access Oct 2026

RSV prefusion F vaccine effectiveness in older adults with immunosuppression: a prespecified analysis of the DAN-RSV trial.

In adults aged 60 years or older, RSVpreF vaccination reduced hospitalisations for RSV-related respiratory tract disease with no statistical evidence of effect modification by immunosuppression status; however, the study was not powered to exclude subgroup differences.

A. Reimer Jensen, M. H. Højbjerg Lassen, N. Johansen et al. · 0 citations
Open access Sep 2026

Clinical and economic impact of bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccination in older adults: a cost-effectiveness analysis for Chile.

BACKGROUND Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract disease in older adults in Chile. Chile's National Immunization Technical Advisory Group (NITAG) recommended RSV vaccination for adults aged ≥60 years with risk factors for severe illness. This study estimated the cost-effectivenes...

Rafael Bolaños, Tomas Eduardo Abbott, A. Shajarizadeh et al. · 0 citations
Review Open access Oct 2026

Efficacy, Effectiveness, and Immunogenicity of the Respiratory Syncytial Virus Prefusion F Vaccine Administered During Pregnancy: Protocol for a Living Systematic Review and Meta-Analysis

Evaluation of vaccine efficacy and effectiveness in preventing RSV-specific and all-cause respiratory disease and immunogenicity in infants and pregnant individuals and a continuously updated synthesis of real-world evidence on maternal RSVPreF vaccination to inform clinical and policy decisions.

Agustina Mazzoni, Ariel Bardach, M. Berrueta et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.